JP2001517709A5 - - Google Patents

Download PDF

Info

Publication number
JP2001517709A5
JP2001517709A5 JP2000513589A JP2000513589A JP2001517709A5 JP 2001517709 A5 JP2001517709 A5 JP 2001517709A5 JP 2000513589 A JP2000513589 A JP 2000513589A JP 2000513589 A JP2000513589 A JP 2000513589A JP 2001517709 A5 JP2001517709 A5 JP 2001517709A5
Authority
JP
Japan
Prior art keywords
cells
composition
mannose
virus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000513589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001517709A (ja
JP4669930B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB1998/001718 external-priority patent/WO1999016455A1/en
Publication of JP2001517709A publication Critical patent/JP2001517709A/ja
Publication of JP2001517709A5 publication Critical patent/JP2001517709A5/ja
Application granted granted Critical
Publication of JP4669930B2 publication Critical patent/JP4669930B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000513589A 1997-09-29 1998-09-29 抗原に対する細胞媒介性免疫応答を誘導するための免疫調節組成物 Expired - Fee Related JP4669930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6059497P 1997-09-29 1997-09-29
US60/060,594 1997-09-29
PCT/IB1998/001718 WO1999016455A1 (en) 1997-09-29 1998-09-29 Mannose receptor bearing cell line and antigen composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010226648A Division JP5192020B2 (ja) 1997-09-29 2010-10-06 抗原に対する細胞障害性t細胞応答を誘導するための医薬品の製造におけるマンノース受容体保有抗原提示細胞の使用方法

Publications (3)

Publication Number Publication Date
JP2001517709A JP2001517709A (ja) 2001-10-09
JP2001517709A5 true JP2001517709A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4669930B2 JP4669930B2 (ja) 2011-04-13

Family

ID=22030506

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000513589A Expired - Fee Related JP4669930B2 (ja) 1997-09-29 1998-09-29 抗原に対する細胞媒介性免疫応答を誘導するための免疫調節組成物
JP2010226648A Expired - Fee Related JP5192020B2 (ja) 1997-09-29 2010-10-06 抗原に対する細胞障害性t細胞応答を誘導するための医薬品の製造におけるマンノース受容体保有抗原提示細胞の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010226648A Expired - Fee Related JP5192020B2 (ja) 1997-09-29 2010-10-06 抗原に対する細胞障害性t細胞応答を誘導するための医薬品の製造におけるマンノース受容体保有抗原提示細胞の使用方法

Country Status (10)

Country Link
US (1) US8771701B2 (cg-RX-API-DMAC7.html)
EP (1) EP1027063B1 (cg-RX-API-DMAC7.html)
JP (2) JP4669930B2 (cg-RX-API-DMAC7.html)
AT (1) ATE422893T1 (cg-RX-API-DMAC7.html)
AU (1) AU754065B2 (cg-RX-API-DMAC7.html)
CA (1) CA2304952C (cg-RX-API-DMAC7.html)
DE (1) DE69840578D1 (cg-RX-API-DMAC7.html)
DK (1) DK1027063T3 (cg-RX-API-DMAC7.html)
ES (1) ES2322212T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999016455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8021667B2 (en) * 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
JP5007409B2 (ja) 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション 樹状細胞に対するヒトモノクローナル抗体
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
AU2001263653B2 (en) * 2000-06-06 2006-06-29 Igavax Pty Ltd Vaccine
WO2004074432A2 (en) 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
WO2013067597A1 (en) * 2011-11-09 2013-05-16 Ascend Biopharmaceuticals Pty Ltd Immunomodulatory conjugates
WO2014012933A1 (en) * 2012-07-16 2014-01-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the generation of non-transformed macrophage cell lines
WO2015119180A1 (ja) * 2014-02-06 2015-08-13 医化学創薬株式会社 ムチン4(muc4)糖ペプチドに対する抗体及びその用途
CN104721795A (zh) * 2015-04-05 2015-06-24 四川双鑫生物科技有限公司 一种治疗百日咳的内服药物及其制备方法
US20230135456A1 (en) * 2020-04-13 2023-05-04 Exoprother Medical Ltd. Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2279422A2 (fr) 1974-07-22 1976-02-20 Inst Nat Sante Rech Med Forme pharmaceutique a base d'interferon
US4720386A (en) 1976-11-24 1988-01-19 Mccollester Duncan L Vaccine and method for immunotherapy of neoplastic disease
JPS61112023A (ja) 1984-11-05 1986-05-30 Tanabe Seiyaku Co Ltd がん細胞傷害活性物質の新規製法
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
EP0326111A3 (en) 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
US5047227A (en) 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
WO1989008711A1 (en) 1988-03-11 1989-09-21 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates
US5229289A (en) 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
JPH01233219A (ja) 1988-03-12 1989-09-19 Nippon Oil & Fats Co Ltd 制癌剤組成物
AU620149B2 (en) 1988-08-18 1992-02-13 Vaxine Pty Ltd Gamma inulin compositions
EP0442926A1 (en) 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
ATE190354T1 (de) 1990-12-20 2000-03-15 Arch Dev Corp The University O Kontrolle der genexpression durch ionisierende strahlung
US5432260A (en) * 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
WO1993006858A1 (en) 1991-10-09 1993-04-15 Dana Farber Cancer Institute, Inc. Lung cancer-associated protein
ZA93216B (en) 1992-01-17 1993-08-18 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant.
JP3043888B2 (ja) 1992-02-20 2000-05-22 森永乳業株式会社 グルコマンナン部分加水分解物を有効成分とする大腸ガン予防剤
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5820872A (en) 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6017527A (en) 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
EP0849275A1 (en) 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
JP5246860B2 (ja) 2008-09-29 2013-07-24 株式会社前川製作所 急速熱処理装置及び急速熱処理装置用ノズル

Similar Documents

Publication Publication Date Title
EP0584348B1 (en) Genetic vaccine for immunodeficiency viruses
Hiroaki et al. The loss of subtypic determinants in alleles, d/y or w/r, on hepatitis B surface antigen
CA2596274A1 (en) Recombinant mva virus, and the use thereof
JP2004536785A5 (cg-RX-API-DMAC7.html)
CA2304952A1 (en) Mannose-receptor bearing cells and antigen conjugate for immunotherapy
Neurath et al. Viral structural components as immunogens of prophylactic value
JPH0553474B2 (cg-RX-API-DMAC7.html)
EP1136077B1 (en) Preparations containing virus-like particles as immunopotentiators administered through the mucosa
CA2349505A1 (en) Nucleic acid constructs for genetic immunization
JP3000569B2 (ja) B型肝炎ウイルスコア抗原のアミノ酸残基配列
Baric et al. A Sindbis virus variant with a cell-determined latent period
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
CN113373179A (zh) 表达SARS-CoV-2纤突蛋白(S)或其变异体的重组VSV病毒及其构建和应用
EP0120922A1 (en) ANTI-VIRAL VACCINES CONTAINING LECTIN FOR DOMESTIC ANIMALS AND THEIR PREPARATION PROCESS.
Ducos et al. Hepatitis B virus (HBV)-specific in vitro antibody production by peripheral blood mononuclear cells (PBMC) after vaccination by recombinant hepatitis B surface antigen (rHBsAg)
Green Chemistry and structure of animal virus particles
JPH02500440A (ja) レトロウイルス疾患の予防および治療
CN121041577A (zh) 包含多个微针的微针递送系统、制备方法和应用
JPWO2002062381A1 (ja) バキュロウイルスベクターワクチン
RU2076735C1 (ru) Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения
Tong et al. In vitro and in vivo replication capacity of the precore region defective hepatitis B virus variants
Mahr et al. Vaccinia recombinants as vaccine vectors
JP2024540976A5 (cg-RX-API-DMAC7.html)
Avanzini et al. Antigen-specific T cell response in infants after recombinant hepatitis B virus vaccination at birth: evaluation of T helper lymphocyte diversity
EP0998301B1 (en) Nucleic acid based immunotherapy of chronic hepatitis b infection